Ceres Inc (CERE): Price and Financial Metrics
CERE Price/Volume Stats
| Current price | $20.27 | 52-week high | $35.98 |
| Prev. close | $20.89 | 52-week low | $19.85 |
| Day low | $20.22 | Volume | 491,800 |
| Day high | $20.84 | Avg. volume | 619,535 |
| 50-day MA | $23.27 | Dividend yield | N/A |
| 200-day MA | $28.35 | Market Cap | 3.19B |
CERE Stock Price Chart Interactive Chart >
Ceres Inc (CERE) Company Bio
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.
Latest CERE News From Around the Web
Below are the latest news stories about CEREVEL THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate CERE as an investment opportunity.
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceCAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023. President and chief executive officer Ron Renaud will participate in a fireside chat at 9:30 AM ET. The live webcast of the fireside chat can be accessed on th |
Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay AttentionWhether you’re a seasoned trader or a novice, the oldest piece of advice in economics still holds true: buy low and sell high. The challenge lies in determining the right time to purchase stocks that are undervalued or to sell those that are overpriced. There are plenty of signs to crack that code, but one of the clearest is the insiders’ trading patterns. The insiders are corporate officers, companies’ higher-ups, whose positions put them ‘in the know.’ Therefore, monitoring their trades, espec |
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesThree new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated |
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2, 2023, before the U.S. financial markets open. Management will host a conference call to discuss second quarter financial results and business updates on Wednesday, August 2 at 8:00 a.m. ET. To access the |
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations OfficerMr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. “I am so pleased to welcome Paul to |
CERE Price Returns
| 1-mo | N/A |
| 3-mo | -35.85% |
| 6-mo | N/A |
| 1-year | -32.75% |
| 3-year | 95.47% |
| 5-year | N/A |
| YTD | -35.73% |
| 2022 | -2.71% |
| 2021 | 95.54% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...